Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 10/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.71 |
| ▸ | MAPKAPK3 | Q16644 | 5/20 | 0.71 |
| ▸ | MAPK6 | Q16659 | 5/20 | 0.71 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.71 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.71 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
| ▸ | FER | P16591 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | MARK3 | P27448 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005413 | 0.86 | MAP2K4 (0.65) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22819364 | 0.83 | MAP2K4 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22801614 | 0.83 | MAP2K4 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5374591 | 0.83 | MAP2K4 (0.71) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL17306449 | 0.81 | MKNK1 (0.87) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22819363 | 0.81 | MAP2K4 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL8251865 | 0.80 | MAP2K4 (0.68) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL22819367 | 0.79 | MAP2K4 (1.00) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5509470 | 0.79 | MKNK1 (0.61) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL16862707 | 0.79 | MAPK10 (0.67) | MAP2K4DCLK1PRKD3MAP4K4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220170904-A1 | SYSTEMS AND METHODS FOR MONITORING BIOLOGICAL TISSUE DEGRADATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-4409234-A | Pyrazoloindazole derivatives and bronchodilating composition | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1983-10-11 | — | — | US | disclosed |
| EP-0023633-B1 | PYRAZOLOINDAZOLE DERIVATIVES AND PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS | Chugai Seiyaku Kabushiki Kaisha (JP) | 1982-11-24 | — | — | EP | disclosed |
| EP-0023633-A1 | Pyrazoloindazole derivatives and process for preparing the same and pharmaceutical compositions | Chugai Seiyaku Kabushiki Kaisha (JP) | 1981-02-11 | — | — | EP | disclosed |
| US-3994890-A | TRANQUILIZERS, ANTIDEPRESSANTS, ANTIINFLAMMATORY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPKAPK3 21/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPKAPK3 21/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | MAP2K4 358/4885MAPK1 171/4885MAPKAPK3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.